David E. Elder, MBChB

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Subspecialty Director, Dermatopathology, Surgical Pathology Section , HUP
Department: Pathology and Laboratory Medicine

Contact information
Division of Anatomic Pathology, 6 Founders
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Office: 215 662 6503
Fax: 215 349 8088
University of Otago School of Medicine, Dunedin, New Zealand , 1969.
University of Otago School of Medicine, Dunedin, New Zealand , 1970.
Diplomate (Clinical Pathology)
University of Otago School of Medicine, Dunedin, New Zealand , 1975.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Studies in diagnosis, prognosis, genetics and therapy of melanoma.

Description of Clinical Expertise

Dermatopathology, with special interest in pathology of melanoma and pigmented lesions.

Selected Publications

Elder, DE, Editor-in-Chief, R Elenitsas, BL Johnson Jr, GF Murphy: Lever's Histopathology of the Skin. Ninth Edition. Lippincott Williams & Wilkins, Philadelphia. ISBN 0-7817-3742-7. Lippincott Williams & Wilkins, 2005.

Kesmodel SB, Giorgos C, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR: Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12(6): 449-458, Jun 2005.

Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research submitted 2005.

Zhang T, Somasundaram R, Caputo L, Van Bell P, Elder D, Czerniecki B, Hotz S, Schuchter L, Fraker D, Spitz FR, Berensci K, Rani P, Marincola F, Qui R, and Herlyn D: Preferential involvement of CX-chemokine receptor-4 and CX-chemokine ligand-12 in T-cell migration toward melanoma cells. Submitted JNCI 2005.

Flaherty KT, Schuchter LM, Tuveson D, Elder D, Van Belle P, Johnson S, Rosen M, Redlinger M, Weber B, O'Dwyer PJ: Wistar Institute/University of Pennsylvana Skin Cancer SPORE Phase II trials of sorafenib (BAY 43-9006) in melanoma: efficacy in combination with chemotherapy and correlative studies of mechanism of action in metastatic melanoma. Annual SPORE meeting, Bethesda, MD. SPORE Annual Meeting Abstracts July 2005.

back to top
Last updated: 08/07/2023
The Trustees of the University of Pennsylvania